DOCSLIB.ORG

Saturday, October 24, 2009 Stool, Scope, Stain Or Scan? 7:50 Am – 5:00 Pm Douglas K

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Saturday, October 24, 2009 Stool, Scope, Stain Or Scan? 7:50 Am – 5:00 Pm Douglas K Join Your Colleagues in San Diego for ACG 2009 The Premier GI Clinical Event of the Year! Dear Colleagues, Welcome to ACG 2009, ACG’s Annual Scientific Meeting and Postgraduate Course, the premier GI clinical event of the year. The Postgraduate Course Directors and ACG’s Educational Affairs Committee, along with Friday Course Directors, have brought together internationally-recognized experts and rising stars in the field. This year’s program promises to deliver the latest clinical updates in gastroenterology and hepatology, plus discuss what is on the horizon that may impact your practice. Abstract submissions for ACG 2009 were the highest in our meeting’s history and nearly 1,300 were selected for presentation at the meeting, with 67 slated for oral presentation and the remainder as poster presentations. I congratulate all of our colleagues for their research efforts and I encourage you to attend the oral presentations and to view the posters during the three-day Annual Meeting. Speaking of posters, we will again offer Poster Rounds with the Experts. Each day of the poster sessions, well-known experts will lead attendees around to posters of interest. This is a great opportunity to discuss posters, garner insight from the expert, and make new contacts with other attendees in a low-key, relaxed atmosphere. Poster Rounds with the Experts runs from Sunday through Tuesday. ACG has been hard at work these past few months building a new ACG member benefit, the ACG GI Circle. The ACG GI Circle is an interactive online community that lets you connect with fellow ACG members in your local community, on the state level, across the U.S. and around the world. When you join the GI Circle, you’ll be able to engage with experts on clinical challenges and the latest science, share your experiences and keep pace with emerging trends, and connect with colleagues and friends to discuss new research and clinical updates presented at ACG meetings or discuss top- of-mind issue like health care policy and practice management challenges. To learn more about the ACG GI Circle and to create your profile, visit the ACG GI Circle booth #1927. Attending ACG 2009 shouldn’t be all work and no play. Plan on attending the President’s Reception, on Monday evening, from 7:00 pm-9:00 pm at the Manchester Grand Hyatt, in the Manchester Ballroom, D-I. Be sure to plan some additional downtime and explore the beautiful city of San Diego. In closing, I want to thank you for the opportunity to serve you this year. It has been my great pleasure to be the ACG President and I welcome everyone to the ACG 2009 Annual Scientific Meeting and Postgraduate Course. Sincerely, Eamonn M.M. Quigley, MD, FACG ACG President 1 For more information on ACG 2009 and to register, visit www.acgmeetings.org Schedule at a Glance Alumni Receptions Thursday, October 22 Saturday, October 24 Sunday, October 25 Consult ACG Registration area for room locations. 6:00 pm - 7:00 pm Registration Continental Breakfast Continental Breakfast Exhibit Hall Lobby Ballroom Foyer Ballroom Foyer 6:00 pm - 8:00 pm 7:00 am - 7:45 am 7:00 am - 7:45 am Monday, October 26 Registration Registration Exhibit Hall Lobby Exhibit Hall Lobby Registration Friday, October 23 7:00 am - 5:15 pm 7:00 am - 6:30 pm Exhibit Hall Lobby 7:00 am - 5:15 pm Postgraduate Course Postgraduate Course Ballroom 20 Ballroom 20 Auxiliary Registration/ Continental Breakfast 7:50 am - 5:00 pm 7:50 am - 5:00 pm Hospitality Suite Outside course room Manchester Grand Hyatt 6:30 am - 8:00 am Auxiliary Registration/ Auxiliary Registration/ Hotel, Betsy Room Hospitality Suite Hospitality Suite 8:00 am - 12:00 noon Registration Manchester Grand Hyatt Manchester Grand Hyatt Exhibit Hall Lobby Hotel, Betsy Room Hotel, Betsy Room Annual Meeting 6:30 am - 8:00 pm 8:00 am - 12:00 noon 8:00 am - 12:00 noon Ballroom 20 8:00 am - 5:15 pm GI Pathophysiology Course ACG Store ACG Store Room 30 B - E Ballroom Lobby Ballroom Lobby ACG Store 7:25 am - 12:30 pm 8:00 am - 5:15 pm 8:00 am - 5:15 pm Ballroom Lobby 8:00 am - 5:30 pm Practice Management David Sun Lecture Exhibit Hall Opens Course Ballroom 20 Exhibit Halls E - H Presidential Address Room 33 A - C 10:00 am - 10:30 am 12:00 noon - 7:00 pm Ballroom 20 8:00 am - 5:00 pm 9:00 am - 9:25 am Optional Learning Job Forum ASGE - Sponsored Luncheons Exhibit Halls E - H Exhibit Hall Endoscopy Course (Ticket required. See ticket 12:00 noon - 7:00 pm Exhibit Halls E - H Room 29 A - D for room assignment.) 9:30 am - 4:00 pm 7:55 am - 5:15 pm 12:20 pm - 1:35 pm Poster Sessions Exhibit Halls E - H Job Forum What’s New in GI Career Opportunities 12:00 noon - 7:00 pm Exhibit Halls E - H Pharmacology Course for Women in GI Luncheon 9:30 am - 4:00 pm Room 30 B - E Room 29 A Optional Learning 1:45 pm - 5:00 pm (Ticket required.) Luncheons Poster Sessions 12:20 pm - 1:35 pm (Ticket required. See ticket Exhibit Halls E - H ACG Store for room assignment.) 10:30 am - 4:00 pm Ballroom Lobby GI Jeopardy 12:10 pm - 1:35 pm 2:00 pm - 6:00 pm Room 29 A - D Lunch Break 5:15 pm - 7:00 pm Trainees Luncheon Food available for Women’s Leadership & (Ticket required.) purchase in Exhibit Halls E - H. Networking Workshop Room 29 A 12:15 pm - 2:00 pm Room 32 B 12:10 pm - 1:35 pm 4:00 pm - 8:00 pm ACG Allied Health FAQ Session – TBA Professionals Symposium Recertification Preparation Exhibit Halls E - H Room 30 A - D and Update Course 12:15 pm - 12:45 pm 12:15 pm - 2:40 pm Room 31 A - C 5:30 pm - 9:00 pm FAQ Session – IBD NEW ! Exhibitor Theater Exhibit Halls E - H Exhibit Hall, Booth #1935 1:00 pm - 1:30 pm 12:30 pm-1:00 pm ACG Job Forum — Gastrojobs 2009 Trainees’ Forum FAQ Session – Liver Exhibit Halls E - H Looking for a job? Recruiting candidates for an open Room 31 ABC 5:15 pm - 7:00 pm 1:15 pm - 1:45 pm position? Gastrojobs, powered by naturejobs, the award- winning scientific and medical online job board, can Women and Minorities help! Gastrojobs will be available live in the Exhibit in GI Reception Hall, Booth 2001, or see what gastrojobs has to offer at Manchester Grand Hyatt Hotel, Molly Room www.nature.com/gastrojobs. 6:00 pm - 7:00 pm 2 Schedule at a Glance SCHEDULES & MAP & SCHEDULES The American Journal of Poster Sessions ACG 2009 Gastroenterology Lecture Exhibit Halls E - H Ballroom 20 AB 10:30 am - 4:00 pm ACG 2009 2:40 pm - 3:20 pm Lunch Break Thanks to Our Sponsors ACG Business Meeting Food available for purchase in Ballroom 20 AB Exhibit Halls E - H. 5:30 pm - 6:00 pm 12:15 pm - 2:00 pm ACG thanks the following sponsors of ACG 2009 ACG members only FAQ Session – Endoscopy exhibit hall events, meeting amenities and International Attendee Exhibit Halls E - H services, and meeting promotional material. Reception 12:30 pm - 1:00 pm Manchester Grand Hyatt Hotel, Manchester FAQ Session – TBA Ballroom A Exhibit Halls E - H AstraZeneca 6:00 pm - 7:00 pm 1:15 pm - 1:45 pm Braintree Laboratories President’s Reception Emily Couric Manchester Grand Hyatt Memorial Lecture Ganeden Biotech Hotel, Manchester Ballroom 20 AB Ballroom D 2:00 pm - 2:45 pm 7:00 pm - 9:00 pm GI Pathology, P.C. LIpath Tuesday, October 27 Wednesday, October 28 Lumenis Optional Breakfast Procter & Gamble Optional Breakfast Sessions Sessions (Ticket required. See ticket (Ticket required. See ticket for room assignment.) PLUS Diagnostics for room assignment.) 6:45 am - 8:30 am 6:45 am - 8:30 am QDX Pathology Services Registration Registration Exhibit Hall Lobby Shire Exhibit Hall Lobby 6:45 am - 12:30 pm 6:45 am - 6:00 pm ACG Store Takeda Pharmaceuticals North America, Inc. Auxiliary Registration/ Ballroom Lobby Hospitality Suite 8:00 am - 12:30 pm UCB, Inc. Manchester Grand Hyatt Hotel, Betsy Room Annual Meeting Vertex Pharmaceuticals 8:00 am - 12:00 noon Ballroom 20 AB 8:30 am - 12:30 pm ACG Store Ballroom Lobby David Y. Graham Lecture 8:00 am - 6:15 pm Ballroom 20 AB 10:15 am - 10:45 am Annual Meeting Ballroom 20 Online Procedures to Claim CME 8:30 am - 6:00 pm Attendees at ACG’s educational activities in San Exhibit Hall Diego may claim CME or print a Certificate of Exhibit Halls E - H 9:30 am - 4:00 pm Attendance in one of two ways: Job Forum 1. Visit one of the CME kiosks located in the San Diego Exhibit Halls E - H Convention Center to complete your evaluation. Print your 9:30 am - 4:00 pm CME or attendance certificate, or email yourself a copy of J. Edward Berk the certificate to print later. Distinguished Lecture OR Ballroom 20 10:00 am - 10:30 am 2. From your own computer, visit the ACG website at www.acg.gi.org to complete your evaluation and print your certificate. 3 Convention Center Floor Plan acg EXhibit hall GROUND ACG CME Area Registration Area Speaker LEVEL Area Elevators and Escalators to Meeting Rooms room rooms room 29 30, 31, 32 33 Ballroom 20 PG Course & Annual Meeting UPPER LEVEL Elevators and Escalators to Registration & Exhibit Hall (exhibits, posters, FAQ sessions) Events Locations: GI Pathophysiology Course (Friday) – Room 30 B-E Allied Health Professionals Symposia (Monday) – Room 30 A-D Practice Management Course (Friday) – Room 33 A-C Presidential Reception (Monday) – Manchester Grand Hyatt, Manchester Ballroom D ASGE Endoscopy Course (Friday) – Room 29 A-D *Tuesday and Wednesday Optional Breakfasts will be GI Pharmacology Course (Friday) – Room 30 B-E held in Rooms 30, 31 and 32 Recertification Course (Friday) – Room 31 A-C Speaker Ready is in Box Office E, near ACG Registration *Saturday & Sunday Optional Learning Lunches will be Job Forum is in the Exhibit Hall, Booth #2001 held in Rooms 29, 30, 31, 32, and 33 Press Room – Room 28 E *specific room locations are listed on event ticket 4 Event Locations — Friday, October 23 page 6:45 am–8:00 am Continental Breakfast Outside course rooms MAP & SCHEDULES 7:00 am–12:30 pm GI Pathophysiology Course* Room 30 B-E 37 ACG 2009 8:00 am–5:00 pm Practice Management Course* Room 33 A-C 29 7:55 am–5:15 pm ASGE-sponsored Endoscopy Course* Room 29 A-D 32 1:45 pm–5:00 pm What’s New in GI Pharmacology Course* Room 30 B-E 39 4:00 pm–8:00 pm Women’s Leadership and Networking Workshop Room 32 B 15 Advanced registration required.
Load more

Recommended publications
  • Malignant Peritoneal Mesothelioma: Clinical Aspects, and Therapeutic Perspectives
    REVIEW ARTICLE Annals of Gastroenterology (2018) 31, 1-11 Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives Stergios Boussiosa, Michele Moschettab, Afroditi Karathanasia, Alexandros K. Tsiourisc, Foivos S. Kanellosc, Konstantina Tatsid, Konstantinos H. Katsanose, Dimitrios K. Christodouloue Medway NHS Foundation Trust, Kent, UK; Sarah Cannon Research Institute, London, UK; University of Ioannina, Greece; General Hospital G. Hatzikosta, Ioannina, Greece Abstract Malignant peritoneal mesothelioma (MPM) is a rare disease with a wide clinical spectrum. It arises from the peritoneal lining and commonly presents with diffuse, extensive spread throughout the abdomen and, more rarely, metastatic spread beyond the abdominal cavity. Computed tomography, magnetic resonance imaging and positron-emission tomography are important diagnostic tools used for the preoperative staging of MPM. The definitive diagnosis is based on histopathological analysis, mainly via immunohistochemistry. In this regard, paired- box gene 8 negativity represents a useful diagnostic biomarker for differentiating MPM from ovarian carcinoma. In addition, BRCA1-associated protein-1 (BAP1) loss is specific to MPM and allows it to be distinguished from both benign mesothelial lesions and ovarian serous tumors. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has become an increasingly important therapeutic approach, while systemic therapies are still being developed. Histology, Ki-67, completeness of cytoreduction,
    [Show full text]
  • Practice Parameters for the Treatment of Patients with Dominantly Inherited Colorectal Cancer
    Practice Parameters For The Treatment Of Patients With Dominantly Inherited Colorectal Cancer Diseases of the Colon & Rectum 2003;46(8):1001-1012 Prepared by: The Standards Task Force The American Society of Colon and Rectal Surgeons James Church, MD; Clifford Simmang, MD; On Behalf of the Collaborative Group of the Americas on Inherited Colorectal Cancer and the Standards Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons is dedicated to assuring high quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus. The standards committee is composed of Society members who are chosen because they have demonstrated expertise in the specialty of colon and rectal surgery. This Committee was created in order to lead international efforts in defining quality care for conditions related to the colon, rectum, and anus. This is accompanied by developing Clinical Practice Guidelines based on the best available evidence. These guidelines are inclusive, and not prescriptive. Their purpose is to provide information on which decisions can be made, rather than dictate a specific form of treatment. These guidelines are intended for the use of all practitioners, health care workers, and patients who desire information about the management of the conditions addressed by the topics covered in these guidelines. Practice Parameters for the Treatment of Patients With Dominantly Inherited Colorectal Cancer Inherited colorectal cancer includes two main syndromes in which predisposition to the disease is based on a germline mutation that may be transmitted from parent to child.
    [Show full text]
  • Genetic/Familial High-Risk Assessment: Colorectal
    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Genetic/Familial High-Risk Assessment: Colorectal Version 2.2019 — August 8, 2019 NCCN.org Continue Version 2.2019, 08/08/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. Printed by PEDRO ANTONIO PARRA BAOS on 11/18/2019 12:12:24 PM. For personal use only. Not approved for distribution. Copyright © 2019 National Comprehensive Cancer Network, Inc., All Rights Reserved. NCCN Guidelines Index NCCN Guidelines Version 2.2019 Table of Contents Genetic/Familial High-Risk Assessment: Colorectal Discussion *Dawn Provenzale, MD, MS/Chair ¤ Þ Michael J. Hall, MD, MS † ∆ Arnold J. Markowitz, MD ¤ Duke Cancer Institute Fox Chase Cancer Center Memorial Sloan Kettering Cancer Center *Samir Gupta, MD/Vice-chair ¤ Amy L. Halverson, MD ¶ Robert J. Mayer, MD † Þ UC San Diego Moores Cancer Center Robert H. Lurie Comprehensive Cancer Dana-Farber/Brigham and Women’s Center of Northwestern University Cancer Center Dennis J. Ahnen, MD ¤ University of Colorado Cancer Center Stanley R. Hamilton, MD ≠ June Mikkelson, MS, CGC ∆ The University of Texas Roswell Park Cancer Institute Lee-May Chen, MD ¶ MD Anderson Cancer Center UCSF Helen Diller Family Reid M. Ness, MD, MPH ¤ Comprehensive Cancer Center Heather Hampel, MS, CGC ∆ Vanderbilt-Ingram Cancer Center The Ohio State University Comprehensive Daniel C. Chung, MD ¤ ∆ Cancer Center - James Cancer Hospital Shajan Peter, MD ¤ Massachusetts General Hospital and Solove Research Institute O'Neal Comprehensive Cancer Center Cancer Center at UAB Sigurdis Haraldsdottir, MD, PhD † Gregory Cooper, MD ¤ Stanford Cancer Institute Scott E.
    [Show full text]
  • Guidelines for the Management of Hereditary Colorectal Cancer
    Guidelines Guidelines for the management of hereditary Gut: first published as 10.1136/gutjnl-2019-319915 on 28 November 2019. Downloaded from colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/ United Kingdom Cancer Genetics Group (UKCGG) Kevin J Monahan ,1,2 Nicola Bradshaw,3 Sunil Dolwani,4 Bianca Desouza,5 Malcolm G Dunlop,6 James E East,7,8 Mohammad Ilyas,9 Asha Kaur,10 Fiona Lalloo,11 Andrew Latchford,12 Matthew D Rutter ,13,14 Ian Tomlinson ,15,16 Huw J W Thomas,1,2 James Hill,11 Hereditary CRC guidelines eDelphi consensus group ► Additional material is ABSTRact having a family history of a first-degree relative published online only. To view Heritable factors account for approximately 35% of (FDR) or second degree relative (SDR) with CRC.2 please visit the journal online (http:// dx. doi. org/ 10. 1136/ colorectal cancer (CRC) risk, and almost 30% of the While highly penetrant syndromes such as Lynch gutjnl- 2019- 319915). population in the UK have a family history of CRC. syndrome (LS), familial adenomatous polyposis (FAP) The quantification of an individual’s lifetime risk of and other polyposis syndromes account for account For numbered affiliations see end of article. gastrointestinal cancer may incorporate clinical and for only 5–10% of all CRC diagnoses, advances molecular data, and depends on accurate phenotypic in genetic diagnosis, improvements in endoscopic Correspondence to assessment and genetic diagnosis. In turn this may surgical control, and medical and lifestyle interven- Dr Kevin J Monahan, Family facilitate targeted risk-reducing interventions, including tions provide opportunities for CRC prevention and Cancer Clinic, St Mark’s endoscopic surveillance, preventative surgery and effective treatment in susceptible individuals.
    [Show full text]
  • Mesothelin's Role As a Biomarker and Therapeutic Target for Malignant
    cancers Review Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma Dannel Yeo 1,2,3 , Laura Castelletti 1,2,3 , Nico van Zandwijk 2,3,4 and John E. J. Rasko 1,2,3,5,* 1 Li Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW 2050, Australia; [email protected] (D.Y.); [email protected] (L.C.) 2 Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia; [email protected] 3 Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney Local Health District (SLHD), Camperdown, NSW 2050, Australia 4 Concord Repatriation General Hospital, Sydney Local Health District (SLHD), Concord, NSW 2139, Australia 5 Gene and Stem Cell Therapy Program, Centenary Institute, The University of Sydney, Camperdown, NSW 2050, Australia * Correspondence: [email protected]; Tel.: +61-295656160 Simple Summary: Mesothelioma is a deadly disease with a dismal prognosis. Since its discovery, mesothelin, a cell surface protein, has been a promising biomarker and therapeutic target due to its overexpression in mesothelioma and limited expression in normal cells. This review summarizes the clinical studies that have examined mesothelin as a biomarker and therapeutic target in mesothelioma and explores future perspectives in its role to improve patient management. Abstract: Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options and poor prognosis. MPM originates from the mesothelial lining of the pleura. Mesothelin Citation: Yeo, D.; Castelletti, L.; van (MSLN) is a glycoprotein expressed at low levels in normal tissues and at high levels in MPM.
    [Show full text]
  • Spinoff 2015 Cover
    Air Revitalization System Enables Excursions to the Stratosphere NASA Technology Now there’s a new story in the works that builds on the nation’s history with high-flying n order to test a parachute system for surviving high-altitude bailouts, from balloons and space travel, and it involves 1959 to 1960 the US Air Force commenced Project Excelsior. It required allowing others the opportunity to see the I Captain Joseph Kittinger to complete a series of jumps from a gondola teth- world from a view that only a select few, such as ered to a helium balloon that had carried him into the stratosphere. On August Kittinger, have ever been allowed to see. 16, 1960, Kittinger completed his most audacious leap from a height of 102,800 The first chapter began as one of NASA’s feet—until recently the highest altitude reached by man in an unpowered aircraft. iconic missions, the Space Shuttle Program, was After achieving a freefall velocity of 714 miles per hour, he landed safely back on coming to an end. The agency had set its sights New Mexico soil. on new horizons, such as sending humans to Kittinger’s risky skydive proved useful for not only pilots but also NASA astro- Mars and designing other spacecraft to explore nauts. Besides the parachute, Kittinger also wore a pressurized suit to withstand the deeper reaches of the solar system. Instead being above what’s known as the Armstrong limit. At approximately 62,000 feet, of using the shuttle to get to the International or roughly 12 miles above Earth’s surface, atmospheric pressure drops so low that Space Station (ISS), astronauts would hitch water boils at temperatures as low as the human body’s.
    [Show full text]
  • The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes Daniel Herzig, M.D
    CLINICAL PRACTICE GUIDELINES The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes Daniel Herzig, M.D. • Karin Hardimann, M.D. • Martin Weiser, M.D. • Nancy Yu, M.D. Ian Paquette, M.D. • Daniel L. Feingold, M.D. • Scott R. Steele, M.D. Prepared by the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons he American Society of Colon and Rectal Surgeons METHODOLOGY (ASCRS) is dedicated to ensuring high-quality pa- tient care by advancing the science, prevention, and These guidelines are built on the last set of the ASCRS T Practice Parameters for the Identification and Testing of management of disorders and diseases of the colon, rectum, Patients at Risk for Dominantly Inherited Colorectal Can- and anus. The Clinical Practice Guidelines Committee is 1 composed of society members who are chosen because they cer published in 2003. An organized search of MEDLINE have demonstrated expertise in the specialty of colon and (1946 to December week 1, 2016) was performed from rectal surgery. This committee was created to lead interna- 1946 through week 4 of September 2016 (Fig. 1). Subject tional efforts in defining quality care for conditions related headings for “adenomatous polyposis coli” (4203 results) to the colon, rectum, and anus, in addition to the devel- and “intestinal polyposis” (445 results) were included, us- opment of Clinical Practice Guidelines based on the best ing focused search. The results were combined (4629 re- available evidence. These guidelines are inclusive and not sults) and limited to English language (3981 results), then prescriptive.
    [Show full text]
  • Combined Endo-Laparoscopic Surgery for Difficult Benign Colorectal Polyps
    485 Review Article (Current Strategies in Colon Cancer Management) Combined endo-laparoscopic surgery for difficult benign colorectal polyps Zhong-Hui Liu1, Li Jiang1, Fion Siu-Yin Chan1,2, Michael Ka-Wah Li3, Joe King-Man Fan1,2,3 1Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China; 2Department of Surgery, The University of Hong Kong, Hong Kong, China; 3Asia-Pacific Endo-Lap Surgery Group (APELS), Hong Kong, China Contributions: (I) Conception and design: JKM Fan, MKW Li; (II) Administrative support: MKW Li; (III) Provision of study materials or patients: FSY Chan; (IV) Collection and assembly of data: ZH Liu, L Jiang; (V) Data analysis and interpretation: ZH Liu; FSY Chan; JKM Fan; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Joe King-Man Fan, MBBS (HK), MS (HKU), FRCSEd, FACS. Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China. Email: [email protected]. Abstract: Prevention of colorectal cancer (CRC) depends largely on the detection and removal of colorectal polyps. Despite the advances in endoscopic techniques, there are still a subgroup of polyps that cannot be treated purely by endoscopic approach, which comprise of about 10–15% of all the polyps. These so-called “difficult colorectal polyps” are polyps with large size, morphology, at difficult location, scarring or due to recurrence, which have historically been managed by surgical segmental resection. In treating benign difficult colorectal polyps, we have to balance the operative risks and morbidities associated with surgical segmental resection. Therefore, combined endoscopic and laparoscopic surgery (CELS) has been developed to remove this subgroup of difficult benign polyps.
    [Show full text]
  • Familial Adenomatous Polyposis Polymnia Galiatsatos, M.D., F.R.C.P.(C),1 and William D
    American Journal of Gastroenterology ISSN 0002-9270 C 2006 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2006.00375.x Published by Blackwell Publishing CME Familial Adenomatous Polyposis Polymnia Galiatsatos, M.D., F.R.C.P.(C),1 and William D. Foulkes, M.B., Ph.D.2 1Division of Gastroenterology, Department of Medicine, The Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada, and 2Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada Familial adenomatous polyposis (FAP) is an autosomal-dominant colorectal cancer syndrome, caused by a germline mutation in the adenomatous polyposis coli (APC) gene, on chromosome 5q21. It is characterized by hundreds of adenomatous colorectal polyps, with an almost inevitable progression to colorectal cancer at an average age of 35 to 40 yr. Associated features include upper gastrointestinal tract polyps, congenital hypertrophy of the retinal pigment epithelium, desmoid tumors, and other extracolonic malignancies. Gardner syndrome is more of a historical subdivision of FAP, characterized by osteomas, dental anomalies, epidermal cysts, and soft tissue tumors. Other specified variants include Turcot syndrome (associated with central nervous system malignancies) and hereditary desmoid disease. Several genotype–phenotype correlations have been observed. Attenuated FAP is a phenotypically distinct entity, presenting with fewer than 100 adenomas. Multiple colorectal adenomas can also be caused by mutations in the human MutY homologue (MYH) gene, in an autosomal recessive condition referred to as MYH associated polyposis (MAP). Endoscopic screening of FAP probands and relatives is advocated as early as the ages of 10–12 yr, with the objective of reducing the occurrence of colorectal cancer.
    [Show full text]
  • 3. Studies of Colorectal Cancer Screening
    IARC HANDBOOKS COLORECTAL CANCER SCREENING VOLUME 17 This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Cancer-Preventive Strategies, which met in Lyon, 14–21 November 2017 LYON, FRANCE - 2019 IARC HANDBOOKS OF CANCER PREVENTION 3. STUDIES OF COLORECTAL CANCER SCREENING 3.1 Methodological considerations end-point of the RCT can be the incidence of the cancer of interest. Methods for colorectal cancer (CRC) screen- The observed effect of screening in RCTs is ing include endoscopic methods and stool-based dependent on, among other things, the partic- tests for blood. The two primary end-points for ipation in the intervention group and the limi- endoscopic CRC screening are (i) finding cancer tation of contamination of the control group. at an early stage (secondary prevention) and Low participation biases the estimate of effect (ii) finding and removing precancerous lesions towards its no-effect value, and therefore it must (adenomatous polyps), to reduce the incidence be evaluated and reported. Screening of controls of CRC (primary prevention). The primary by services outside of the RCT also dilutes the end-point for stool-based tests is finding cancer effect of screening on CRC incidence and/or at an early stage. Stool-based tests also have some mortality. If the screening modality being eval- ability to detect adenomatous polyps; therefore, a uated is widely used in clinical practice in secondary end-point of these tests is reducing the the region or regions where the RCT is being incidence of CRC. conducted, then contamination may be consid- erable, although it may be difficult and/or costly 3.1.1 Randomized controlled trials of to estimate its extent.
    [Show full text]
  • Durwood “Skip” Ringo to Receive the 2015 Cliff Henderson Trophy
    FOR IMMEDIATE RELEASE Contact: Stephanie Berry 703-416-4888 Ext 104 [email protected] Durwood “Skip” Ringo to Receive the 2015 Cliff Henderson Trophy Washington, DC, June 15, 2015 – The National Aeronautic Association (NAA) is proud to announce that Durwood “Skip” Ringo has been selected as the recipient of the 2015 Cliff Henderson Trophy. The Henderson Trophy, which is in the collection of the Smithsonian’s National Air and Space Museum, was established in 1960 to honor the creator and Managing Director of the world- renowned National Air Races from 1928-1939. His work stimulated a generation’s interest in aviation and challenged the state of the art in aviation development. The trophy is awarded to “…a living individual, group of individuals, or an organization whose vision, leadership or skill made a significant and lasting contribution to the promotion and advancement of aviation and aerospace in the United States.” Previous recipients include Colonel Joseph Kittinger, USAF (Ret.), Joe Lombardo, Marion Blakey, The United States Air Force Academy, Anne Morrow Lindbergh, Lieutenant General James H. Doolittle, Senator Barry M. Goldwater, Clarence L. “Kelly” Johnson, and Scott Crossfield. Ringo received his Bachelor’s degree in Civil Engineering from the Citadel in 1967 and also holds a Master of Engineering degree in Industrial Engineering from the University of Florida and a Master of Arts degree in National Security and Strategic Studies from the College of Naval Warfare. Ringo has also completed the Kennedy School of Government’s Program for Senior Executives in National and International Security at Harvard University. Commissioned in the U.S.
    [Show full text]
  • The Longest Leap
    The Longest Leap Heroism is not limited orate technology and a team of ex- was suffering extreme pain in his to combat, but the valor perts in several fields, came close to right hand that was caused by par- being his last. In November 1959. he tial failure of pressure in that glove of only a few, like Joe bailed out of a balloon at 76.000 feet. during the ascent. Kittinger, is tested in the highest anyone had been in an After he had fallen for four min- both peace and war. open gondola. His small stabilizing utes and thirty-seven seconds. Kit- chute, which was to prevent a flat lingers main chute opened. and BY JOHN L. FRISBEE spin that could be fatal at rotation some eight minutes later he landed CONTRIBUTING EDITOR speeds of 150 to 200 rpm. malfunc- at the White Sands MissileRange in tioned and wrapped around his New Mexico with no permanent in- I N 1934, the Air Force abandoned, neck. He dropped unconscious to juries but with three world records: seemingly for all time, its lighter- 12,000 feet, where his main chute the highest open-gondola balloon than-air program that included both saved the day. Three weeks later, he ascent, the longest free-fall, and the balloons and airships. 'No decades jumped without incident from longest parachute descent. He was later, the tremendous advances that 74,000 feet. In September 1%0. also the first man logo supersonic in had been made in aviation technolo- President Eisenhower presented the a free-fall.
    [Show full text]